BREAKING: Johnson & Johnson's COVID vaccine wins FDA panel backing, setting up likely authorization Lilly scores $210M supply deal for newly authorized coronavirus antibody cocktail One Medical CEO refutes claims that clinics gave COVID-19 vaccines to ineligible clients Pfizer's COVID-19 vaccine rollout could heat up after FDA clears warmer storage requirements FDA tells Merck to show more data for its OncoImmune COVID-19 drug as EUA pushed back COVID-19 is exacerbating physician retention and burnout. Here are some tips to address it Biopharma roundup—Pfizer examines two approaches to variants Cigna's Evernorth to acquire telehealth company MDLive Vials maker Stevanto plans IPO as coronavirus vaccine companies clamor for packaging: Reuters Epizyme shouldn't blame COVID-19 alone for sluggish launch of its cancer med Tazverik: analysts Featured Story | By Eric Sagonowsky A month after Johnson & Johnson's COVID-19 vaccine posted positive data in a phase 3 study, the shot is almost ready for prime time. Late Friday, a key panel unanimously endorsed the vaccine for emergency use and sent it to the agency for an official decision. read more |
| |
|---|
|
Top Stories By Eric Sagonowsky As U.S. officials look to ramp up COVID-19 vaccinations heading into March, they’re not overlooking another pandemic-fighting tool. Eli Lilly on Friday scored a government supply deal for its newly authorized antibody cocktail, which dramatically reduced deaths and hospitalizations in a late-stage trial. read more By Heather Landi One Medical CEO Amir Dan Rubin denied Thursday that the company's clinics gave COVID-19 vaccines to ineligible clients "unless they abused our trust." But three Bay Area counties have suspended coronavirus vaccine supplies to One Medical under allegations that its procedures allowed ineligible individuals to cut the line. read more By Fraiser Kansteiner Pfizer and BioNTech’s COVID-19 vaccine Comirnaty can now be stored and transported at standard pharmaceutical freezer temps, the FDA said Thursday. The move should simplify deliveries of the vaccine, previously strapped by stringent sub-zero storage requirements, at a critical time in the U.S. vaccine rollout. read more By Ben Adams Merck will no longer be able to supply an experimental COVID drug from its $425 million buyout of OncoImmune to the U.S. government under a $356 million contract as the FDA has demanded more data, delaying its supply. read more By Heather Landi The COVID-19 pandemic has taken an extreme toll on physicians who were already reporting symptoms of burnout at alarming rates. COVID-19’s impact on front-line healthcare staff will unfold for years to come, but it appears to have already had an effect on physicians’ career plans, according to a new survey. Here are tips to improve doctor retention. read more By Kevin Dunleavy,Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Conor Hale The FDA will allow the Pfizer COVID-19 vaccine to be stored at higher temperatures. Merck's virus drug deal with U.S. is off after the FDA asked for more data on the med. Doctors Without Borders appeals to J&J. Albany Molecular signs on with Pfizer. New coronavirus variant in California. read more By Paige Minemyer Cigna will acquire telehealth platform MDLive, the insurer announced Friday morning. read more By Kevin Dunleavy Stevanto, an Italian maker of glass vials, plans to launch an initial public offering this year. With vaccine vials a hot commodity, the company has been doing a booming business since the start of the pandemic—and it's already beefed up capacity worldwide. read more By Fraiser Kansteiner Hopes were high last winter for Epizyme's new cancer med Tazverik, which bagged two FDA approvals over a five-month stretch. When full-year sales came in below the mark, execs blamed COVID-19 for hobbling the rollout. But there could be more to Tazverik's sluggish start than the pandemic, some analysts figure. read more |
